JP2025504375A5 - - Google Patents
Info
- Publication number
- JP2025504375A5 JP2025504375A5 JP2024540881A JP2024540881A JP2025504375A5 JP 2025504375 A5 JP2025504375 A5 JP 2025504375A5 JP 2024540881 A JP2024540881 A JP 2024540881A JP 2024540881 A JP2024540881 A JP 2024540881A JP 2025504375 A5 JP2025504375 A5 JP 2025504375A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- minutes
- target protein
- approximately
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297245P | 2022-01-07 | 2022-01-07 | |
| US63/297,245 | 2022-01-07 | ||
| PCT/US2023/060253 WO2023133522A2 (en) | 2022-01-07 | 2023-01-06 | Tissue-specific imaging and therapeutic agents targeting proteins expressed on muscle cell surface |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504375A JP2025504375A (ja) | 2025-02-12 |
| JP2025504375A5 true JP2025504375A5 (https=) | 2026-01-14 |
Family
ID=87074312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540881A Pending JP2025504375A (ja) | 2022-01-07 | 2023-01-06 | 筋細胞表面上で発現されるタンパク質を標的とする組織特異的イメージング及び治療剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250025569A1 (https=) |
| EP (1) | EP4460333A4 (https=) |
| JP (1) | JP2025504375A (https=) |
| KR (1) | KR20240130136A (https=) |
| CN (1) | CN119053346A (https=) |
| AU (1) | AU2023205141A1 (https=) |
| CA (1) | CA3242927A1 (https=) |
| IL (1) | IL314093A (https=) |
| TW (1) | TW202345894A (https=) |
| WO (1) | WO2023133522A2 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413740B1 (en) * | 1995-12-15 | 2002-07-02 | Regeneron Pharmaceuticals, Inc. | Tyrosine kinase receptors and ligands |
| US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| WO2019074489A1 (en) * | 2017-10-10 | 2019-04-18 | Flagship Biosciences, Inc. | METHODS FOR QUANTITATIVE EVALUATION OF MUSCLE FIBERS IN MUSCLE DYSTROPHY |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| KR20220125801A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
-
2023
- 2023-01-06 TW TW112100633A patent/TW202345894A/zh unknown
- 2023-01-06 CA CA3242927A patent/CA3242927A1/en active Pending
- 2023-01-06 WO PCT/US2023/060253 patent/WO2023133522A2/en not_active Ceased
- 2023-01-06 KR KR1020247026374A patent/KR20240130136A/ko active Pending
- 2023-01-06 CN CN202380021119.4A patent/CN119053346A/zh active Pending
- 2023-01-06 AU AU2023205141A patent/AU2023205141A1/en active Pending
- 2023-01-06 JP JP2024540881A patent/JP2025504375A/ja active Pending
- 2023-01-06 EP EP23737794.0A patent/EP4460333A4/en active Pending
- 2023-01-06 IL IL314093A patent/IL314093A/en unknown
-
2024
- 2024-07-02 US US18/762,429 patent/US20250025569A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11964021B2 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
| Mou et al. | Two-in-one chemogene assembled from drug-integrated antisense oligonucleotides to reverse chemoresistance | |
| Schon et al. | Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis | |
| JP2008537752A5 (https=) | ||
| JP2008537752A (ja) | がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 | |
| JP2008537551A5 (https=) | ||
| RU2020113027A (ru) | Axl-специфичные антитела и их применения | |
| Chen et al. | Co-delivery strategies based on multifunctional nanocarriers for cancer therapy | |
| Chang et al. | Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice | |
| WO2024061356A1 (zh) | 抑制tubb2基因表达的干扰rna及其应用 | |
| EP3493852A1 (en) | Targeted nanodroplet emulsions for treating cancer | |
| De Souza et al. | Novel therapeutic modalities to address nondrugable protein interaction targets | |
| Tyagi et al. | Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome | |
| JP2025504375A5 (https=) | ||
| Fei et al. | Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs | |
| Wang et al. | Poly (ester amine) composed of polyethylenimine and pluronic enhance delivery of antisense oligonucleotides in vitro and in dystrophic mdx mice | |
| WO2022109022A1 (en) | Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases | |
| Krishnan et al. | drug review | |
| Craig | Macrophage-Targeted Oligonucleotide Therapeutics to Downregulate Inflammatory Cytokines in Non-Alcoholic Steatohepatitis | |
| WO2025106529A2 (en) | Compositions for targeting muscle cells and uses thereof | |
| WO2025199292A1 (en) | A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer | |
| Asai et al. | Nanoparticle-mediated RNA interference for cancer therapy | |
| Oh et al. | 547 POSTER Effect of the extract of Taraxacum officinale on inflammation induced by anti-cancer treatment | |
| Oncology | overcome the challenges of finding the right conjugate to target a cell type and the right linker to optimize the therapy, conjugates are still limited in the size of the payload they can deliver. | |
| NZ709680B2 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |